FDA finds no evidence linking semaglutide to suicidal behaviours
However, the agency notes officials cannot rule out that 'a small risk may exist', and it will continue to investigate.
In a preliminary review, the US Food and Drug Administration (FDA) says it has found no evidence drugs like semaglutide cause suicidal thoughts or actions.
Still, the agency noted officials cannot rule out that “a small risk may exist”, and it will continue to look into similar reports involving these GLP-1 receptor agonists.
